U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C16H19ClN2O.C4H4O4
Molecular Weight 406.8607
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of CARBINOXAMINE MALEATE

SMILES

CN(C)CCOC(c1ccc(cc1)Cl)c2ccccn2.C(\[H])(=C(\[H])/C(=O)O)/C(=O)O

InChI

InChIKey=GVNWHCVWDRNXAZ-BTJKTKAUSA-N
InChI=1S/C16H19ClN2O.C4H4O4/c1-19(2)11-12-20-16(15-5-3-4-10-18-15)13-6-8-14(17)9-7-13;5-3(6)1-2-4(7)8/h3-10,16H,11-12H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1-

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including: https://www.drugs.com/pro/carbinoxamine.html

Carbinoxamine is a histamine-H1 receptor blocking agent. It is an antihistamine with anticholinergic (drying) and sedative properties. Carbinoxamine appears to compete with histamine (type H1) for receptor sites on effector cells in the gastrointestinal tract, blood vessels and respiratory tract. Carbinoxamine is effective for the symptomatic treatment of seasonal and perennial allergic rhinitis; vasomotor rhinitis; allergic conjunctivitis due to inhalant allergens and foods; mild, uncomplicated allergic skin manifestations of urticaria and angioedema; dermatographism; as therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Most common adverse reactions are: sedation, sleepiness, dizziness, disturbed coordination, epigastric distress, and thickening of bronchial secretions. Avoid concomitant use of alcohol and CNS depressants (hypnotics sedatives, tranquilizers, etc.) due to additive adverse effects.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
2.3 nM [Ki]
Target ID: CHEMBL289
Sources: DOI: 10.14896/jssxmeeting.21.0.296.1
25.0 µM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
CARBINOXAMINE MALEATE

Approved Use

Carbinoxamine maleate is effective for the symptomatic treatment of: Seasonal and perennial allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Dermatographism. As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Amelioration of the severity of allergic reactions to blood or plasma.

Launch Date

1.04803199E12
Palliative
CARBINOXAMINE MALEATE

Approved Use

Carbinoxamine maleate is effective for the symptomatic treatment of: Seasonal and perennial allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Dermatographism. As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Amelioration of the severity of allergic reactions to blood or plasma.

Launch Date

1.04803199E12
Palliative
CARBINOXAMINE MALEATE

Approved Use

Carbinoxamine maleate is effective for the symptomatic treatment of: Seasonal and perennial allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Dermatographism. As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Amelioration of the severity of allergic reactions to blood or plasma.

Launch Date

1.04803199E12
Palliative
CARBINOXAMINE MALEATE

Approved Use

Carbinoxamine maleate is effective for the symptomatic treatment of: Seasonal and perennial allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Dermatographism. As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Amelioration of the severity of allergic reactions to blood or plasma.

Launch Date

1.04803199E12
Palliative
CARBINOXAMINE MALEATE

Approved Use

Carbinoxamine maleate is effective for the symptomatic treatment of: Seasonal and perennial allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Dermatographism. As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Amelioration of the severity of allergic reactions to blood or plasma.

Launch Date

1.04803199E12
Palliative
CARBINOXAMINE MALEATE

Approved Use

Carbinoxamine maleate is effective for the symptomatic treatment of: Seasonal and perennial allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Dermatographism. As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Amelioration of the severity of allergic reactions to blood or plasma.

Launch Date

1.04803199E12
Palliative
CARBINOXAMINE MALEATE

Approved Use

Carbinoxamine maleate is effective for the symptomatic treatment of: Seasonal and perennial allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Dermatographism. As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Amelioration of the severity of allergic reactions to blood or plasma.

Launch Date

1.04803199E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
16.9 ng/mL
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered: PHENYLPROPANOLAMINE
CARBINOXAMINE MALEATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
13.5 ng/mL
4 mg 2 times / day multiple, oral
dose: 4 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: PHENYLEPHRINE
CARBINOXAMINE MALEATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
4.5 ng/mL
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered: PHENYLEPHRINE
CARBINOXAMINE MALEATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
14.5 h
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered: PHENYLPROPANOLAMINE
CARBINOXAMINE MALEATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
22 h
4 mg 2 times / day multiple, oral
dose: 4 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: PHENYLEPHRINE
CARBINOXAMINE MALEATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
30 h
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered: PHENYLEPHRINE
CARBINOXAMINE MALEATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
31%
unknown, unknown
CARBINOXAMINE MALEATE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
PubMed

PubMed

TitleDatePubMed
[Antimycobacterial antihistaminics].
1989 Aug
Cold-syrup induced movement disorder.
2001 Jun
Quantitation of antihistamines in pharmaceutical preparations by liquid chromatography with a micellar mobile phase of sodium dodecyl sulfate and pentanol.
2001 Nov-Dec
Characterization of antihistamine-human serum protein interactions by capillary electrophoresis.
2007 Apr 20
Possible role of pseudoephedrine and other over-the-counter cold medications in the deaths of very young children.
2007 Mar
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.
2010 Dec
4-(4-Chloro-phen-yl)-4-hy-droxy-piperidinium maleate maleic acid solvate.
2010 Jul 14
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Patents

Sample Use Guides

Tablets: 1 or 2 tablets (4 to 8 mg) 3 to 4 times daily Oral Solution: 1 or 2 teaspoonfuls (4 to 8 mg) 3 to 4 times daily.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Name Type Language
CARBINOXAMINE MALEATE
JAN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD  
Common Name English
2-(P-CHLORO-.ALPHA.-(2-(DIMETHYLAMINO)ETHOXY)BENZYL)PYRIDINE MALEATE (1:1)
Common Name English
CARBINOXAMINE MALEATE [USP]
Common Name English
CARBINOXAMINE MALEATE [WHO-DD]
Common Name English
CARBINOXAMINE MALEATE [VANDF]
Common Name English
ETHANAMINE, 2-((4-CHLOROPHENYL)-2-PYRIDINYLMETHOXY)-N,N-DIMETHYL-, (Z)-2-BUTENEDIOATE (1:1)
Systematic Name English
CLISTIN
Brand Name English
CARBINOXAMINE MALEATE [MI]
Common Name English
NSC-62362
Code English
CARBINOXAMINE MALEATE [ORANGE BOOK]
Common Name English
CARBINOXAMINE MALEATE [USP-RS]
Common Name English
CARBINOXAMINE MALEATE [JAN]
Common Name English
CARBINOXAMINE MALEATE [MART.]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29578
Created by admin on Sat Jun 26 12:24:11 UTC 2021 , Edited by admin on Sat Jun 26 12:24:11 UTC 2021
Code System Code Type Description
DRUG BANK
DBSALT000963
Created by admin on Sat Jun 26 12:24:11 UTC 2021 , Edited by admin on Sat Jun 26 12:24:11 UTC 2021
PRIMARY
PUBCHEM
5282409
Created by admin on Sat Jun 26 12:24:11 UTC 2021 , Edited by admin on Sat Jun 26 12:24:11 UTC 2021
PRIMARY
NCI_THESAURUS
C47432
Created by admin on Sat Jun 26 12:24:11 UTC 2021 , Edited by admin on Sat Jun 26 12:24:11 UTC 2021
PRIMARY
EVMPD
SUB01044MIG
Created by admin on Sat Jun 26 12:24:11 UTC 2021 , Edited by admin on Sat Jun 26 12:24:11 UTC 2021
PRIMARY
EPA CompTox
3505-38-2
Created by admin on Sat Jun 26 12:24:11 UTC 2021 , Edited by admin on Sat Jun 26 12:24:11 UTC 2021
PRIMARY
MERCK INDEX
M3070
Created by admin on Sat Jun 26 12:24:11 UTC 2021 , Edited by admin on Sat Jun 26 12:24:11 UTC 2021
PRIMARY Merck Index
MESH
C004649
Created by admin on Sat Jun 26 12:24:11 UTC 2021 , Edited by admin on Sat Jun 26 12:24:11 UTC 2021
PRIMARY
CAS
3505-38-2
Created by admin on Sat Jun 26 12:24:11 UTC 2021 , Edited by admin on Sat Jun 26 12:24:11 UTC 2021
PRIMARY
FDA UNII
02O55696WH
Created by admin on Sat Jun 26 12:24:11 UTC 2021 , Edited by admin on Sat Jun 26 12:24:11 UTC 2021
PRIMARY
USP_CATALOG
1096000
Created by admin on Sat Jun 26 12:24:11 UTC 2021 , Edited by admin on Sat Jun 26 12:24:11 UTC 2021
PRIMARY USP-RS
ECHA (EC/EINECS)
222-498-0
Created by admin on Sat Jun 26 12:24:11 UTC 2021 , Edited by admin on Sat Jun 26 12:24:11 UTC 2021
PRIMARY
RXCUI
91066
Created by admin on Sat Jun 26 12:24:11 UTC 2021 , Edited by admin on Sat Jun 26 12:24:11 UTC 2021
PRIMARY RxNorm
ChEMBL
CHEMBL864
Created by admin on Sat Jun 26 12:24:11 UTC 2021 , Edited by admin on Sat Jun 26 12:24:11 UTC 2021
PRIMARY